Personally, I think he retired. Maybe he got a better offer for somewhere else, but I believe he retired. It'll be interesting to see though if he does show up somewhere else. Might want to invest in that company.
MACK leadership is the biggest short there is. Pretty sure anytime the stock starts to rise they say, "lets spend more money so it will go down."
Yeah, cnbc wasn't showing anything. Figures nothing major was going on. Looks like we are in for a wait. I guess Onivyde sales were a bit lighter than expected. That's not good.
Apparently Baxter hasn't gotten their act together yet. They get an F.
came in today. Voted against Bob and the other top two. Voted against extra compensation for them. These d-bags need to get the picture that the shareholders are NOT please!
that the sellers have dried up and the buyers are just waiting for the green light. Then it's off to the races. Look at the volume. Barely 10k as of this post.
Why do you bring this up when they have said they aren't partnering? If I'm not mistaken, the have been emphatic on NOT partnering.
saw a LOT of UA gear being worn including some of the new work out shirts. I bought a Boston Red Sox shirt the other day as well as one of the Rock's shirts. Then I saw an add with a UA tied to CPT America and Iron Man. If UA is breaking into the super hero market, this is huge!!! Kids and adults buy that #$%$ like crazy. This is a buy and hold stock.
the shorts are bailing ahead of the EMA decision. Typically if the results are positive from the EMA that has a good effect on a stock. Then again, this is MACK........
Before I start my rant, I want you to know I hold shares. So I'm not just spouting off.
1. MACK CEO and staff reads from a script for every CC. That makes me nervous in the sense that they don't truly know their company or what they did for the quarter.
2. The CEO indicated there would be a partner for MM-121 by end of 2015. Nothing there.
3. Wall Street has lost all confidence in that company. Seriously, how do you get FDA approval and in one day drop 30%
1. Their finance deal they pulled off at the EOY was good. Great timing considering the crash.
2. Their launch of Onivyde appears to be going very well. I am concerned with their rate of burn on their other compounds.
Finally, this is the most aggravating piece. They constantly say they are not for sale. Since the CEO couldn't get a partnership for MM-121 by EOY, one has to wonder.
So I'm very concerned with MACK and really hope they don't screw it all up. It does seem that they have potential, but management is extra special IMO.
I agree. I was thinking about that today. I think they decided with there current cash to bring these other two compounds to market based off of the potential they see. Also, they have mentioned that they are willing to partner but want to let the data mature. Thats been said in the last two CCs. If the data is good, I expect late this year or next year as well. At least they aren't stupid like MACK.
Shorty, totally agree with that sentiment. He mentioned that a couple times. He's not a very excitable fellow, but in this instance you could sense his excitement.
As for dosage, he laid it out in the beginning of the call, the four things they wanted to do and one of them was treat frequently. I would imagine that once you get a dosage you are good with but can't treat very frequently that the next step would be to try to move the treatment schedule up. Which they have. Now it seems they can go back to increasing the dosage which sounded like they expect two more jumps: 2mg and 4mg. That's a LOT! If I'm not mistaken
Finally, I really like listening to him on the CC. He is always at ease with his company, doesn't read from a script and totally owns his business.
Oh and I'm not sure if he meant to say that or not, but he WAS talking to a senior manager at a big pharma in a causal manner. They guy has contacts in good places if you ask me. I think we see some partnerships later on this year. Just my personal opinion.
Anyone have any thoughts? I thought it sounded good. A couple new molecules being submitted. I'm not sure what the dosage they were at equates to in cohorts but it sounded like a log.